Director at Sarepta (NASDAQ: SRPT) exercises 10,500 options, withholds shares

Rhea-AI Filing Summary

Sarepta Therapeutics director Claude Nicaise exercised stock options and adjusted his shareholdings. On January 29, 2026, he exercised 10,500 stock options at $13.71 per share, receiving 10,500 shares of common stock.

On the same date, 6,780 common shares were withheld by Sarepta, noted as satisfying payment of the option exercise price. After these transactions, Nicaise directly owned 31,532 shares of Sarepta common stock.

Insider Trade Summary

10,500 shares exercised/converted

Mixed 3 txns

Insider Nicaise Claude

Role Director

Type	Security	Shares	Price	Value
Exercise	Stock Option (right to buy)	10,500	$0.00	--
Exercise	Common Stock	10,500	$13.71	$144K
Tax Withholding	Common Stock	6,780	$21.23	$144K

Holdings After Transaction: Stock Option (right to buy) — 0 shares (Direct); Common Stock — 38,312 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Nicaise Claude

(Last) (First) (Middle)

215 FIRST STREET

SUITE 415

(Street)

CAMBRIDGE MA 02142

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Sarepta Therapeutics, Inc. [ SRPT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/29/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/29/2026		M		10,500	A	$13.71	38,312	D
Common Stock	01/29/2026		F(1)		6,780	D	$21.23	31,532	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$13.71	01/29/2026		M			10,500	02/28/2017	02/28/2026	Common Stock	10,500	$0	0	D

Explanation of Responses:

1. Represents shares withheld by the Issuer to satisfy payment by the Reporting Person of the option exercise price. The Reporting Person holds the exercised shares not wittheld by the Issuer.

	/s/ Cristin L. Rothfuss, as Attorney-in-Fact for Claude Nicaise	01/29/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider activity did Sarepta Therapeutics (SRPT) report in this Form 4?

Sarepta reported that director Claude Nicaise exercised 10,500 stock options and adjusted his common stock holdings. Some shares were withheld by the company, and he ended with 31,532 directly owned Sarepta common shares after the transactions.

How many Sarepta (SRPT) stock options did Claude Nicaise exercise?

Claude Nicaise exercised 10,500 Sarepta stock options on January 29, 2026. The options had a stated exercise price of $13.71 per share and were granted in 2017 with an expiration date in 2026, converting into an equal number of common shares.

How many Sarepta (SRPT) shares were withheld in the January 29, 2026 transaction?

Sarepta withheld 6,780 common shares from Claude Nicaise on January 29, 2026. The filing explains these shares were retained by the issuer to satisfy payment of the option exercise price, with the remaining exercised shares continuing to be held by Nicaise.

What is Claude Nicaise’s Sarepta (SRPT) share ownership after this Form 4?

After the reported transactions, Claude Nicaise directly owned 31,532 Sarepta common shares. This figure reflects the 10,500 shares acquired through option exercise, minus the 6,780 shares withheld by Sarepta, as detailed in the Form 4 filing.

What roles does the reporting person hold at Sarepta Therapeutics (SRPT)?

The reporting person, Claude Nicaise, is identified as a director of Sarepta Therapeutics. The Form 4 indicates he is not an officer and not a ten percent owner, and he filed the report individually as one reporting person.

What derivative security was involved in the Sarepta (SRPT) Form 4 filing?

The derivative security was a stock option to buy Sarepta common stock. It covered 10,500 shares at an exercise price of $13.71, became exercisable from a 2017 grant, and carried an expiration date of February 28, 2026, before being fully exercised.